20180830 IN Pipeline – Healthcare & Life Sciences


“Rare disease is becoming an increasing area of focus in the pharmaceutical industry, with a market size estimated to reach $169B by 2022.” -CB Insight

Learn More:  htt://bit.ly/2opzjHS

Periodic-Table-of-Rare-Disease_v5-1024x448

IN PIPELINE – HEALTHCARE DEALS 08-30-2018

• RootPath, a Cambridge-based biotechnology developing personalized T cell therapies for cancer, raised $7 million in seed funding. Sequoia Chinaled the round, and was joined by investors including Volcanics Venture, BV (Baidu Ventures) and Nest.Bio Ventures.

Nebula Genomics, a San Francisco and Boston-based human genome sequencing and health big data company, raised $4.3 million in seed funding. Investors include Khosla Ventures, Arch Venture Partners, Fenbushi Capital, Mayfield, F-Prime Capital Partners, Great Point Ventures, Windham Venture Partners, Hemi Ventures, Mirae Asset, Hikma Ventures and Heartbeat Labs.

Nanovis, a seller of nano-technology enhanced spinal implants, raised $5.5 million in funding.   Investors include Elevate Ventures, 1st Source Capital Corporation, Purdue’s Foundry Investment Fund, Commenda Capital and Ellipsis Ventures.

Harbour BioMed, a China-based biopharmaceutical company, raised $85 million in Series B funding. GIC Private Ltd led the round, and was joined by investors including China Life Private Equity Investment Co, Vertex Ventures, AdvanTech and Legend Capital.

 

 

 

 

 

 

 

 

Author: JD Morris

Learn more about JD Biography on LinkedIn: http://www.linkedin.com/in/jdmorris

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s